Study S001426

Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes - Effects on Glucose Metabolism, Prevention of Weight Regain and Peripheral Tissue Metabolic Activation

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04854083
Acronym: MitoSema
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 50
Start: 2022-02-17
Primary completion: 2025-08
Lead sponsor: Kirsi Pietiläinen
Conditions: Type2 Diabetes
Interventions: DRUG:Semaglutide, 1.34 mg/mL; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

HbA1c [from baseline to 12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.